Is Mono Pharmacare overvalued or undervalued?

As of 18 September 2025, the valuation grade for Mono Pharmacare has moved from fair to expensive. This indicates that the company is currently overvalued. The key ratios supporting this assessment include a PE ratio of 13.69, an EV to EBITDA ratio of 12.47, and a PEG ratio of 0.51, which, while relatively low, do not justify the current price given the overall market context.
In comparison to its peers, Mono Pharmacare's valuation stands out as expensive, especially when juxtaposed with Sun Pharma, which has a PE ratio of 34.46, and Cipla, which is considered attractive with a PE ratio of 23.65. Additionally, the company's recent stock performance has been underwhelming, with a year-to-date return of -30.88%, contrasting sharply with the Sensex's positive return of 7.52% in the same period. This further reinforces the conclusion that Mono Pharmacare is overvalued in the current market environment.